Nektar TherapeuticsNKTRNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank36
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P36
Within normal range
vs 5Y Ago
-4x
Contraction
Streak
2 yr
Consecutive declineDecelerating
PeriodValue
2025-18.67%
20248.77%
202336.64%
202226.33%
2021-31.72%
20204.68%
2019-145.76%
2018993.15%
201731.28%
2016-60.12%